Federal health advisers are rejecting the first-ever proposal to use MDMA as a treatment for PTSD
Federal health advisers voted Tuesday against a first-of-a-kind proposal to begin using the mind-altering drug
— sometimes called ecstasy or molly. Panelists pointed to flawed studies that could have skewed the results, missing follow-up data on patient outcomes and a lack of diversity among participants. The vast majority of patients studied were white, with only five Black patients receiving is the first in a series of psychedelics — including LSD and psilocybin — that are expected to come before the FDA in the next few years. The panel’s negative ruling could further derail financial investments in the fledgling industry, which has mainly been funded by a small number of wealthy backers.
or a dummy pill. That’s the opposite of the approach generally required for high-quality drug research, in which bias is minimized by “blinding” patients and researchers to whether they received the drug under investigation. “I’m not convinced at all that this drug is effective based on the data I saw,” said Dr. Rajesh Narendran, a University of Pittsburgh psychiatrist who chaired the panel.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Panel rejects psychedelic drug MDMA as PTSD treatment in possible setback for advocatesFederal health advisers voted Tuesday against a first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for PTSD.
Read more »
Panel rejects psychedelic drug MDMA as a PTSD treatment in possible setback for advocatesFederal health advisers voted Tuesday against a first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for PTSD,
Read more »
Panel rejects psychedelic drug MDMA as a PTSD treatment in possible setback for advocatesThe panel of advisers to the Food and Drug Administration voted 10-1 against the overall benefits of MDMA when used to treat post-traumatic stress disorder
Read more »
FDA panel votes against MDMA for PTSD, setting up hurdle to approvalFDA advisers cited a variety of concerns with the trials submitted by Lykos Therapeutics as part of the application.
Read more »
Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are weighing the first-of-a-kind approval of MDMA, the mind-altering club drug, as a treatment for PTSD
Read more »
MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationBy Matthew Perrone | Associated Press WASHINGTON — Federal health advisers are weighing the first-of-a-kind approval of MDMA, the mind-altering club drug, as a treatment for PTSD — part of a decade…
Read more »